Skip to main content

62 - References

References

60 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 References

  1. Samara MT, et al. Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. Cochrane Database Syst Rev 2018; (5):CD011884.
  2. Barnes T, et al. Evidence-­based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2020; 34:3–78.
  3. Rubio JM, et al. Early non-­response to antipsychotic treatment in schizophrenia: a systematic review and meta-­analysis of evidence-­based management options. CNS Drugs 2023; 37:499–512.
  4. Ezewuzie N, et al. Establishing a dose–response relationship for oral risperidone in relapsed schizophrenia. J Psychopharm 2006; 20:86–90.
  5. Sparshatt A, et al. Quetiapine: dose–response relationship in schizophrenia. CNS Drugs 2008; 22:49–68.
  6. Honer WG, et al. A randomized, double-­blind, placebo-­controlled study of the safety and tolerability of high-­dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. J Clin Psychiatry 2012; 73:13–20.
  7. Davis JM, et al. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 2004; 24:192–208.
  8. Leucht S, et al. Dose–response meta-­analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry 2020; 177:342–353.
  9. Srisurapanont M, et al. A network meta-­analysis of the dose-­response effects of lurasidone on acute schizophrenia. Sci Rep 2021; 11:5571.
  10. Kinon BJ, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-­ blind, fixed-­dose study. J Clin Psychopharmacol 2008; 28:392–400.
  11. Marder SR, et al. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825–835.
  12. Van Putten T, et al. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990; 47:754–758.
  13. Zimbroff DL, et al. Controlled, dose-­response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. Am J Psychiatry 1997; 154:782–791.
  14. Siafis S, et al. Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-­effects: a systematic review and dose–response meta-­analysis. Mol Psychiatry 2023; 28:3267–3277.
  15. Kinon BJ, et al. Treatment of neuroleptic-­resistant schizophrenic relapse. Psychopharmacol Bull 1993; 29:309–314.
  16. Hermes E, et al. Predictors of antipsychotic dose changes in the CATIE schizophrenia trial. Psychiatry Res 2012; 199:1–7.
  17. Loebel A, et al. Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-­controlled study. J Clin Psychiatry 2016; 77:1672–1680.
  18. Jukic MM, et al. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. Lancet Psychiatry 2019; 6:418–426.
  19. Taylor D, et al. Predicting clozapine dose required to achieve a therapeutic plasma concentration: a comparison of a population algorithm and three algorithms based on gene variant models. J Psychopharmacol 2023; 37:1030–1039.
  20. Patel MX, et al. Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales. Eur Neuropsychopharmacol 2014; 24:499–509.
  21. Stokes I, et al. Prevalence of treatment resistance and clozapine use in early intervention services. BJPsych Open 2020; 6:e107.
  22. Paton C, et al. Is clozapine really under-­used? Investigating clinical practice in a community psychosis team. J Psychiatry Behav Sci 2023; 6:1089.
  23. Heres S, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-­to-­head comparison studies of second-­generation antipsychotics. Am J Psychiatry 2006; 163:185–194.
  24. Obayashi Y, et  al. Switching strategies for  antipsychotic monotherapy in  schizophrenia: a  multi-­center cohort study of  aripiprazole. Psychopharmacology (Berl) 2020; 237:167–175.
  25. Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry 2007; 68 Suppl 6:10–13.
  26. Takeuchi H, et al. Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-­analysis. Schizophr Bull 2017; 43:862–871.
  27. Stroup TS, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006; 163:611–622.
  28. Leucht S, et al. Second-­generation versus first-­generation antipsychotic drugs for schizophrenia: a meta-­analysis. Lancet 2009; 373:31–41.
  29. Leucht S, et al. A meta-­analysis of head-­to-­head comparisons of second-­generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166:152–163.
  30. Hong J, et al. Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-­month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-­SOHO) study. BMC Psychiatry 2012; 12:218.
  31. Agid O, et al. Antipsychotic response in first-­episode schizophrenia: efficacy of high doses and switching. Eur Neuropsychopharmacol 2013; 23:1017–1022.
  32. Gannon L, et  al. High-­dose olanzapine in treatment-­resistant schizophrenia: a systematic review. Ther Adv Psychopharmacol 2023; 13:20451253231168788.
  33. Dong S, et al. A network meta-­analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-­resistant schizophrenia. Eur Arch Psychiatry Clin Neurosci 2023; 274:917–928.
  34. Stroup TS, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011; 168:947–956.
  35. Montastruc F, et al. Association of aripiprazole with the risk for psychiatric hospitalization, self-­harm, or suicide. JAMA Psychiatry 2019; 76:409–417.

Schizophrenia and related psychoses CHAPTER 1 36. Pae CU, et al. Effectiveness and tolerability of switching to aripiprazole once monthly from antipsychotic polypharmacy and/or other long acting injectable antipsychotics for patients with schizophrenia in routine practice: a retrospective, observation study. Clin Psychopharmacol Neurosc 2020; 18:153–158. 37. Prescribing Observatory for Mental Health. Topic 1h & 3e: Prescribing of antipsychotic medication in adult mental health services, including high dose, combined, and PRN. CCQI 422. 2022 (last accessed February 2025); https://www.rcpsych.ac.uk/improving-­care/ccqi/national-­ clinical-­audits/pomh. 38. Wagner E, et al. Clozapine combination and augmentation strategies in patients with schizophrenia - ­recommendations from an international expert survey among the Treatment Response and Resistance in Psychosis (TRRIP) working group. Schizophr Bull 2020; 46:1459–1470. 39. Taylor DM, et al. Augmentation of clozapine with a second antipsychotic: a meta-­analysis of randomized, placebo-­controlled studies. Acta Psychiatr Scand 2009; 119:419–425. 40. Grover S, et  al. Augmentation strategies for clozapine resistance: a systematic review and meta-­analysis. Acta Neuropsychiatr 2023; 35:65–75. 41. Kapur S, et al. Increased dopamine D2 receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry 2001; 158:311–314. 42. Galling B, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-­analysis and meta-­regression analysis. World Psychiatry 2017; 16:77–89. 43. Gallego JA, et al. Safety and tolerability of antipsychotic polypharmacy. Expert Opin Drug Saf 2012; 11:527–542. 44. Barnes T, et al. Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs 2011; 25:383–399. 45. Taipale H, et al. Safety of antipsychotic polypharmacy versus monotherapy in a nationwide cohort of 61,889 patients with schizophrenia. Am J Psychiatry 2023; 180:377–385. 46. Borlido C, et al. Switching from 2 antipsychotics to 1 antipsychotic in schizophrenia: a randomized, double-­blind, placebo-­controlled study. J Clin Psychiatry 2016; 77:e14–e20. 47. Hori H, et al. Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients. J Psychiatr Res 2013; 47:1843–1848. 48. Essock SM, et al. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 2011; 168:702–708. 49. Constantine RJ, et al. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial. Schizophr Res 2015; 166:194–200. 50. Royal College of Psychiatrists. The Risks and Benefits of High-­Dose Antipsychotic Medication. College Report CR190. London: Royal College of Psychiatrists; 2014.

No comments to display

Back to top